Yonsei Med J.  2006 Aug;47(4):480-484. 10.3349/ymj.2006.47.4.480.

Prevalence of Inducible Clindamycin Resistance in Staphylococcal Isolates at a Korean Tertiary Care Hospital

• Lim HS
• Lee H
• Roh KH
• Yum JH
• Yong D
• Lee K
• Chong Y

• KMID: 1779496
• DOI: http://doi.org/10.3349/ymj.2006.47.4.480

Abstract

Clindamycin resistance in Staphylococcus species can be either constitutive or inducible. Inducible resistance cannot be detected by the conventional antimicrobial susceptibility test. In this study, we determined the prevalence of inducible clindamycin resistance in staphylococcal isolates at a Korean tertiary care hospital. Between February and September 2004, 1,519 isolates of Staphylococcus aureus and 1,043 isolates of coagulase-negative staphylococci (CNS) were tested for inducible resistance by the D-zone test. Overall, 17% of MRSA, 84% of MSSA, 37% of MRCNS, and 70% of MSCNS were susceptible to clindamycin. Of the erythromycin non-susceptible, clindamycin-susceptible isolates, 32% of MRSA, 35% of MSSA, 90% of MRCNS, and 94% of MSCNS had inducible clindamycin resistance. Inducible clindamycin resistance in staphylococci was highly prevalent in Korea. This study indicates importance of the D-zone test in detecting inducible clindamycin resistance in staphylococci to aid in the optimal treatment of patients.

Keyword

Staphylococcus; clindamycin; antibiotic resistance

MeSH Terms

Staphylococcus aureus/metabolism
Staphylococcal Infections/*metabolism
Prevalence
*Microbial Sensitivity Tests
Korea
Humans
Drug Resistance, Multiple, Bacterial
*Drug Resistance, Microbial
Clindamycin/*pharmacology
Anti-Infective Agents/*pharmacology
Anti-Bacterial Agents/*pharmacology

Reference

1. Lee K, Park KH, Jeong SH, Lim HS, Shin JH, Yong D, et al. Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. In Korea: 2003 KONSAR surveillance. Yonsei Med J. 2006. 47:43–54.

2. Frank AL, Marcinak JF, Mangat PD, Tjhio JT, Kelkar S, Schreckenberger PC, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J. 2002. 21:530–534.

3. Martinez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003. 22:593–598.

4. Ladhani S, Garbash M. Staphylococcal skin infections in children: rational drug therapy recommendations. Paediatr Drugs. 2005. 7:77–102.

5. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother. 1991. 35:1267–1272.

6. Weisblum B. Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI, editors. Resistance to the macrolide-lincosamide-streptogramin antibiotics. In gram-positive pathogens. 2000. Washington DC: ASM Press;694.

7. Drinkovic D, Fuller ER, Shore KP, Holland DJ, Ellis-Pegler R. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother. 2001. 48:315–316.

8. Jorgensen JH, Crawford SA, McElmeel ML, Fiebelkorn KR. Detection of inducible clindamycin resistance of staphylococci in conjunction with performance of automated broth susceptibility testing. J Clin Microbiol. 2004. 42:1800–1802.

9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement M100-S14. 2005. Wayne, PA: CLSI.

10. Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol. 2003. 41:4740–4744.

11. Sanchez ML, Flint KK, Jones RN. Occurrence of macrolide-lincosamide-streptogramin resistances among staphylococcal clinical isolates at a university medical center. Is false susceptibility to new macrolides and clindamycin a contemporary clinical and in vitro testing problem? Diagn Microbiol Infect Dis. 1993. 16:205–213.

12. Lampson BC, Parisi JT. Naturally occurring Staphylococcus epidermidis plasmid expressing constitutive macrolide-lincosamide-streptogramin B resistance contains a deleted attenuator. J Bacteriol. 1986. 166:479–483.

13. Rao GG. Should clindamycin be used in treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrob Chemother. 2000. 45:715–716.

14. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis. 2003. 37:1257–1260.

15. Schreckenberger PC, Ilendo E, Ristow KL. Incidence of constitutive and inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci in a community and a tertiary care hospital. J Clin Microbiol. 2004. 42:2777–2779.

16. Almer LS, Shortridge VD, Nilius AM, Beyer JM, Soni NB, Bui MH, et al. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis. 2002. 43:225–232.